Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury.
Shenzhen, China. In Medicine (baltimore), 31 Oct 2015
UNASSIGNED: Currently 2 difference classes of cyclooxygenase (COX)-2 inhibitors, coxibs and relatively selective COX-2 inhibitors, are available for patients requiring nonsteroidal anti-inflammatory drug (NSAID) therapy; their gastroprotective effect is hardly directly compared.The aim of this study was to compare the gastroprotective effect of relatively selective COX-2 inhibitors with coxibs.MEDLINE, EMBASE, and the Cochrane Library (from their inception to March 2015) were searched for potential eligible studies.We included randomized controlled trials comparing coxibs (celecoxib, etoricoxib, parecoxib, and lumiracoxib), relatively selective COX-2 inhibitors (nabumetone, meloxicam, and etodolac), and nonselective NSAIDs with a study duration ≥4 weeks.Comparative effectiveness and safety data were pooled by Bayesian network meta-analysis.
Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.
Winnipeg, Canada. In Adv Nutr, 30 Sep 2015
They are formed via cyclooxygenase, lipoxygenase, and cytochrome P450 pathways, resulting in the formation of prostaglandins, thromboxanes, mono-, di-, and tri-hydroxy fatty acids (FAs), epoxy FAs, lipoxins, eoxins, hepoxilins, resolvins, protectins (also called neuroprotectins in the brain), and maresins.
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance.
More papers using
Houston, United States. In Nature, Feb 2015
In vivo administration of the cyclooxygenase-2 (COX2) inhibitor celecoxib effectively abolishes a PGE2- and COX2-mediated wound response gene signature, and attenuates progressive manifestation of chemoresistance in xenograft tumours, including primary xenografts derived from a patient who was resistant to chemotherapy.